E126: Video Understanding Tech, Creator Economy Innovator, and AI Drug Discovery

Venture Pill

Our Social Media Pages, follow us and engage with the Pill-grim community!

Join our Entre Community

Instagram

Twitter

YouTube

TikTok

LinkedIn

On this week’s dose, we start (1:47) with a breakdown on Twelve Labs, a startup that’s building a video understanding platform driven by leading perceptual-reasoning research, fresh off a $50M Series A. Then (6:14), we discuss Workweek, a startup that manages creators of widely popular business-related newsletters and podcasts and is launching a niche-focused networking platform for its audience base, hot off a $12.5M Series A. Lastly (11:42), we close out this week’s dose with a deepdive on Enveda, a startup that is revolutionizing drug discovery by combining ancient remedies with AI, and their $55M Series B2.

Sources:

https://www.twelvelabs.io/

https://www.bloomberg.com/news/articles/2024-06-04/nvidia-s-latest-investment-is-an-ai-startup-focusing-on-video-search?srnd=homepage-asia

https://www.twelvelabs.io/blog/series-a-announcement

https://workweek.com/membership/

https://www.axios.com/2024/06/13/workweek-raises-125m

https://www.envedabio.com/

https://techcrunch.com/2024/06/14/enveda-raises-55m-to-combine-ancient-remedies-with-ai-for-drug-discovery/

https://pragmaticdlt.com/news/enveda-biosciences-raises-55m-to-revolutionize-drug-discovery-with-ai-and-ancient-remedies/

Music Credit: Chapter One by Cole Bauer and Dean Keeton

https://www.instagram.com/colebauer/

https://www.instagram.com/deankeeton/?hl=en

Disclosure:

The views, statements, and opinions, expressed herein by the hosts and guests are their own, and their appearance on the podcast should not be construed as reflecting the views or implied endorsement of Independent Brokerage Solutions LLC or any of its officers, employees, or agents. The statements made herein should not be considered an investment opinion, advice, or a recommendation regarding securities of any company. This podcast is produced solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy a security.